An investigation on behalf of investors of Cellectis SA (ADR) (NASDAQ:CLLS) shares over potential securities laws violations by Cellectis SA (ADR) (NASDAQ:CLLS and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Cellectis SA (ADR) (NASDAQ:CLLS) concerning whether a series of statements by Cellectis SA (ADR) (NASDAQ:CLLS regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. Cellectis SA reported that its annual Total Revenue declined from 56.38 million EUR in 2015 to 51.01 million EUR in 2016 and that its Net Loss increased from 20.55 million EUR in 2015 to 60.78 million EUR in 2016.

On September 5, 2017, Cellectis SA announced the U.S. Food and Drug Administration's suspension of two early-stage studies for the Company's experimental blood cancer treatment UCART123, following the death of a patient.

Shares of Cellectis SA (ADR) (NASDAQ:CLLS) declined on September 5, 2017 to $23.89 per share.